Imaging Endpoints Exploring Improved Evaluation Response Approaches

August 17, 2021 – Imaging Endpoints’ Chief Medical Officer Ron Korn, MD, PhD, says MRI inflammatory changes caused by various forms of treatments “can look the same and confound the ability to accurately measure treatment response. Over the years, several pharmacokinetic models have been developed based upon the rate and extent of gadolinium contrast enhancement to help distinguish inflammation (pseudoprogression) from true tumor growth. But if you have an immune PET agent that binds to where the killer cells are located (CD8 T Cells), it may become a preferred approach to evaluate response or distinguish true tumor progression from pseudoprogression.”

Learn more about our imaging approaches at ImagingEndpoints.com.